Peptinnovate Ltd (‘Peptinnovate’ or the ‘Company’, a biotechnology company developing novel immune modulators for immunological and inflammatory diseases, announces that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect. The new website for Immune Regulation is www.immuneregulation.com.
“IRL201805 is currently in clinical development for rheumatoid arthritis. Along with our other lead drug candidate PIN201104, currently in clinical development for asthma and dermatological indications, we now have two therapeutic development programmes that have successfully completed early stage clinical studies. We are continuing to execute on our vision to develop these first in class immune-modulators in a broad range of immunological and inflammatory diseases.”
Immune Regulation also announces a significant strengthening of its Board of Directors and scientific team with the appointment of Dr Dominik Escher as Non-Executive Director and Vice Chairman, Dr Ben Cons as Non-Executive Investor Director and Dr Roly Foulkes as Chief Scientific Officer (CSO).
Dr Dominik Escher, Ph.D. has significant experience as a successful biotechnology entrepreneur and a leader in therapeutic development in both the start-up and corporate pharmaceutical environments. He was founder and former CEO of ESBATech, whose ophthalmology business was acquired by Alcon, in a deal valued at up to $589m, and later integrated into Novartis. He has held multiple senior positions, including Board member, Vice President, and CEO at several other companies, including Delenex Therapeutics, CDR-Life, and Pureos Bioventures. Dominik obtained his Ph.D. from the University of Zurich. He is also a board member of the Swiss Biotech Association, which he has led as President since 2013.
Dr Ben Cons has more than 30 years’ experience in pharmaceutical R&D & commercialisation in the biotech, pharmaceutical and financing sectors. Ben has 20 years of experience with the NYSE-listed pharmaceutical services company IQVIA and the associated NovaQuest investment fund. He is currently a Special Partner at the private equity fund Vitruvian and a board advisor to Talking Medicines. He is also an investment member of private capital group, 24Haymarket and an investment panel member at Future Care Capital, a charity focusing on future health and social care policy.
Dr Roly Foulkes is an internationally recognised leader in drug discovery and development, with extensive experience in immunology. His latest role was Vice President Immunology Research at UCB where he was also Chair of the Immunology Therapeutic Area Strategy Team, and Head of Immunology Discovery Research. Since 2012, he has advised small and medium sized biopharma companies within the immunology field, to develop competitive therapeutic strategies and bring new innovative molecules to the clinic.
Commenting on the appointments, Prof. Clive Page, Chairman of Immune Regulation said,
“The appointment of these three experienced industry executives will bring valuable insight and resource to our Board and executive team. With their skills in immunology, clinical therapeutic development and strategy we have the expertise to advance our clinical programmes and look forward to the next stage of our progress.”
In the first half of 2018, Immune Regulation successfully closed a funding round, raising £4 million. The round was co-led by founding investor Metellus and new investor 24Haymarket through the issue of equity.
Richard Nagle, CEO
+44 (0)1438 906978
Melanie Toyne-Sewell / Rozi Morris
+44 (0)20 7457 2020
About Immune Regulation
Formerly known as Peptinnovate Ltd, Immune Regulation is a drug development company developing ‘first in class’ immune resetting therapies for asthma and other chronic inflammatory diseases. The products under development by Immune Regulation have the potential to significantly advance the control and management of a range of chronic inflammatory diseases, with the potential for immune regulation, disease modification and remission.
PIN201104, is uniquely safe and efficacious demonstrating immunoregulatory activity in a number of preclinical models. It has successfully completed Phase 1 clinical development and has the potential to be the first Immune Resetting Asthma Drug (IMRAD).
IRL201805 or ‘1805, has shown promising data following a single dose in a Phase 1/2a human study in patients with rheumatoid arthritis and published in the peer-reviewed journal, Rheumatology. Similar to ‘1104, ‘1805 has shown a safety and side effect profile similar to placebo in this study.